My ePortfolio Register   

13th Congress of the EADO /
Intralesional T-VEC and combinations for melanoma

3rd - 6th May 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 18.05.17
Views: 1343
Rating:

Prof Sanjiv Agarwala - St. Luke's Cancer Center, Easton, USA

Prof Agarwala speaks with ecancer at EADO 2017 about intralesional therapies, including oncolytic talimogene laherparepvec (T-VEC), to treat melanoma.

He highlights the complementary roles of intralesional therapies with systemic therapies including immunotherapeutics, and that local injections can 'warm up' tumours, increasing immune penetration.

Prof Agarwala highlights upcoming trials in combination with pembrolizumab and ipilimumab, and his view of future combination or sequencing of combined treatments.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence